Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221210 | 0.88 | MAPT (0.43) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5216830 | 0.86 | MAPT (0.49) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5218310 | 0.82 | MAPT (0.48) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL475604 | 0.76 | ALDH1A1 (0.53) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL1936887 | 0.75 | MAPT (0.58) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL267897 | 0.73 | KMT2A (0.54) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL4746770 | 0.73 | MEN1 (0.63) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5225589 | 0.72 | ALDH1A1 (0.49) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL13598611 | 0.72 | ALDH1A1 (0.52) | MAPTLMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5221233 | 0.71 | NPC1 (0.46) | MAPTLMNAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | MAPT 16/4885LMNA 1062/4885KMT2A 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.